Identification of tumor antigens in malignant mesothelioma

Kim,Ye‑Rin; Song,Myung‑Ha; Lee,Jun‑Won; Bae,Jae‑Ho; Kim,Jong‑Eun; Kang,Dong‑Muk; Lee,Sang‑Yull

doi:10.3892/ol.2017.6805

Identification of tumor antigens in malignant mesothelioma

Authors:
- Ye‑Rin Kim
- Myung‑Ha Song
- Jun‑Won Lee
- Jae‑Ho Bae
- Jong‑Eun Kim
- Dong‑Muk Kang
- Sang‑Yull Lee
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Pusan National University, Yangsan, Gyeongsangnam 50612, Republic of Korea, Department of Life Science and Genetic Engineering, Paichai University, Daejeon 35345, Republic of Korea, Occupational and Environmental Medicine, Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam 50612, Republic of Korea, Environmental Health Center for Asbestos, Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam 50612, Republic of Korea
Published online on: August 24, 2017 https://doi.org/10.3892/ol.2017.6805
Pages: 4557-4562
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Serological analysis of recombinant tumor cDNA expression library (SEREX) is a powerful and widely used method to explore the cancer immune environment. In the present study, immunoscreening of normal testicular tissues and malignant mesothelioma (MM) cancer MSTO‑211H cell line cDNA libraries with sera from 5 MM patients led to the isolation of 16 independent antigens, which were designated ‘Korea Pusan‑Malignant Mesothelioma’ (KP‑MM)‑1 to ‑16. In total, 3/16 antigens were identified using the results of previous SEREX analyses, and 13 were newly identified. Of these, KP‑MM‑8, which was subsequently identified as amyotrophic lateral sclerosis 2 chromosome region candidate 11, was shown to be tissue‑restricted. Reverse transcription‑polymerase chain reaction demonstrated KP‑MM‑8 to be expressed strongly only in the normal testis, and weakly in the spleen, prostate, ovary, heart and skeletal muscle. In addition, KP‑MM‑8 mRNA was identified in MM cell lines, and in various other cancer cell lines, including MM (3/4), lung cancer (5/7), melanoma (5/7) and liver cancer (5/5) cell lines. Additionally, 2/16 antigens (KP‑MM‑2 and KP‑MM‑6) exclusively reacted with sera from cancer patients. However, KP‑MM‑8 reacted with 1 of 8 MM sera. Notably, 8/8 patients with MM and 8/8 normal individuals exhibited antibodies reactive to KP‑MM‑5, which was identified as cell division cycle 25B, a known oncogene. Overall, this data suggests that KP‑MM‑8 may be considered as a cancer/testis‑like antigen and KP‑MM‑5 as an immunogenic tumor antigen in MM patients.

View Figures

View References

1	Raptopoulos V: Peritoneal mesothelioma. Crit Rev Diagn Imaging. 24:293–328. 1985.PubMed/NCBI
2	Cunha P, Luz Z, Seves I, Sousa C, Skiappa, Ribeiro L, Marques C and Oliveira M: Malignant peritoneal mesothelioma-diagnostic and therapeutic difficulties. Acta Med Port. 15:383–386. 2002.(In Portuguese). PubMed/NCBI
3	Ahmed I, Tipu Ahmed S and Ishtiaq S: Malignant mesothelioma. Pak J Med Sci. 29:1433–1438. 2013.PubMed/NCBI
4	Røe OD and Stella GM: Malignant pleural mesothelioma: History, controversy and future of a manmade epidemic. Eur Respir Rev. 24:115–131. 2015. View Article : Google Scholar : PubMed/NCBI
5	Mirabelli D, Roberti S, Gangemi M, Rosato R, Ricceri F, Merler E, Gennaro V, Mangone L, Gorini G, Pascucci C, et al: Survival of peritoneal malignant mesothelioma in Italy: A population-based study. Int J Cancer. 124:194–200. 2009. View Article : Google Scholar : PubMed/NCBI
6	Rudd RM: Malignant mesothelioma. Br Med Bull. 93:105–123. 2010. View Article : Google Scholar : PubMed/NCBI
7	Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
8	Kondola S, Manners D and Nowak AK: Malignant pleural mesothelioma: An update on diagnosis and treatment options. Ther Adv Respir Dis. 10:275–288. 2016. View Article : Google Scholar : PubMed/NCBI
9	Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, et al: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 180:35–42. 1994. View Article : Google Scholar : PubMed/NCBI
10	Labrecque S, Naor N, Thomson D and Matlashewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res. 53:3468–3471. 1993.PubMed/NCBI
11	Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, et al: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:16–20. 1994.PubMed/NCBI
12	Boon T, Coulie PG and Van den Eynde B: Tumor antigens recognized by T cells. Immunol Today. 18:267–268. 1997. View Article : Google Scholar : PubMed/NCBI
13	Chen YT, Güre AO, Tsang S, Stockert E, Jäger E, Knuth A and Old LJ: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA. 95:6919–6923. 1998. View Article : Google Scholar : PubMed/NCBI
14	van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde BJ, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol. 178:2617–2621. 2007.PubMed/NCBI
15	Caballero OL and Chen YT: Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci. 100:2014–2021. 2009. View Article : Google Scholar : PubMed/NCBI
16	Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I and Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 92:11810–11813. 1995. View Article : Google Scholar : PubMed/NCBI
17	Türeci O, Sahin U, Zwick C, Koslowski M, Seitz G and Pfreundschuh M: Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci USA. 95:5211–5216. 1998. View Article : Google Scholar : PubMed/NCBI
18	Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M and Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
19	Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ and Scanlan MJ: Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA. 100:2651–2656. 2003. View Article : Google Scholar : PubMed/NCBI
20	Song MH, Ha JM, Shin DH, Lee CH, Old L and Lee SY: KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer. Int J Oncol. 41:1820–1826. 2012. View Article : Google Scholar : PubMed/NCBI
21	Suri A, Jagadish N, Saini S and Gupta N: Targeting cancer testis antigens for biomarkers and immunotherapy in colorectal cancer: Current status and challenges. World J Gastrointest Oncol. 7:492–502. 2015.PubMed/NCBI
22	Grah JJ, Katalinic D, Juretic A, Santek F and Samarzija M: Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer. Tumori. 100:60–68. 2014.PubMed/NCBI
23	Sigalotti L, Coral S, Altomonte M, Natali L, Gaudino G, Cacciotti P, Libener R, Colizzi F, Vianale G, Martini F, et al: Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer. 86:979–982. 2002. View Article : Google Scholar : PubMed/NCBI
24	Gaykalova DA, Vatapalli R, Wei Y, Tsai HL, Wang H, Zhang C, Hennessey PT, Guo T, Tan M, Li R, et al: Outlier analysis defines zinc finger gene family DNA methylation in tumors and saliva of head and neck cancer patients. PLoS One. 10:e01421482015. View Article : Google Scholar : PubMed/NCBI
25	Hentati A, Bejaoui K, Pericak-Vance MA, Hentati F, Speer MC, Hung WY, Figlewicz DA, Haines J, Rimmler J, Ben Hamida C, et al: Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nat Genet. 7:425–428. 1994. View Article : Google Scholar : PubMed/NCBI
26	Kiyokawa H and Ray D: In vivo roles of CDC25 phosphatases: Biological insight into the anti-cancer therapeutic targets. Anticancer Agents Med Chem. 8:832–836. 2008. View Article : Google Scholar : PubMed/NCBI
27	Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M and Beach D: CDC25 phosphatases as potential human oncogenes. Science. 269:1575–1577. 1995. View Article : Google Scholar : PubMed/NCBI
28	Kristjánsdóttir K and Rudolph J: Cdc25 phosphatases and cancer. Chem Biol. 11:1043–1051. 2004. View Article : Google Scholar : PubMed/NCBI
29	Kim J, Singh AK, Takata Y, Lin K, Shen J, Lu Y, Kerenyi MA, Orkin SH and Chen T: LSD1 is essential for oocyte meiotic progression by regulating CDC25B expression in mice. Nat Commun. 6:101162015. View Article : Google Scholar : PubMed/NCBI